Stock Scorecard



Stock Summary for Merus N.V (MRUS) - $44.61 as of 3/28/2025 8:28:01 PM EST

Total Score

8 out of 30

Safety Score

44 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MRUS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MRUS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MRUS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MRUS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MRUS (44 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MRUS

Merus Shares Are Up Today: What's Going On? - Merus ( NASDAQ:MRUS ) 2/18/2025 8:25:00 PM
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Fortis ( NYSE:FTS ) , GE Vernova ( NYSE:GEV ) 2/13/2025 1:06:00 PM
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer 2/5/2025 10:00:00 PM
What's Going On With Merus Stock Monday? - Biohaven ( NYSE:BHVN ) , Merus ( NASDAQ:MRUS ) 1/13/2025 9:17:00 PM
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs 1/13/2025 1:04:00 AM
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - Merus ( NASDAQ:MRUS ) 12/16/2024 9:01:00 PM
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - Merus ( NASDAQ:MRUS ) 12/7/2024 6:30:00 AM
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC 12/7/2024 6:30:00 AM
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' - General Motors ( NYSE:GM ) , Allison Transmission ( NYSE:ALSN ) 12/5/2024 2:03:00 PM
Merus Announces FDA Approval of BIZENGRI® ( zenocutuzumab-zbco ) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non-Small Cell Lung Cancer ( NSCLC ) Based on Safety and Efficacy Data From the eNRGy Study - Merus ( NASDAQ:MRUS ) 12/4/2024 9:55:00 PM

Financial Details for MRUS

Company Overview

Ticker MRUS
Company Name Merus N.V
Country USA
Description Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/6/2025

Stock Price History

Last Day Price 44.61
Price 4 Years Ago 31.80
Last Day Price Updated 3/28/2025 8:28:01 PM EST
Last Day Volume 396,453
Average Daily Volume 678,991
52-Week High 61.61
52-Week Low 37.77
Last Price to 52 Week Low 18.11%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -10.34
Free Cash Flow Ratio 4.88
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 8.32
Total Cash Per Share 9.15
Book Value Per Share Most Recent Quarter 9.41
Price to Book Ratio 4.74
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 84.99
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 69,090,000
Market Capitalization 3,082,104,900
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -18.10%
Reported EPS 12 Trailing Months -3.35
Reported EPS Past Year -3.35
Reported EPS Prior Year -2.99
Net Income Twelve Trailing Months -244,556,000
Net Income Past Year -154,939,000
Net Income Prior Year -131,194,000
Quarterly Revenue Growth YOY 2.20%
5-Year Revenue Growth 2.75%
Operating Margin Twelve Trailing Months -970.00%

Balance Sheet

Total Cash Most Recent Quarter 632,268,000
Total Cash Past Year 354,376,000
Total Cash Prior Year 326,700,000
Net Cash Position Most Recent Quarter 632,268,000
Net Cash Position Past Year 354,376,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 356,343,000
Total Stockholder Equity Prior Year 247,055,000
Total Stockholder Equity Most Recent Quarter 703,261,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -157,309,000
Free Cash Flow Per Share Twelve Trailing Months -2.28
Free Cash Flow Past Year -146,189,000
Free Cash Flow Prior Year -157,538,000

Options

Put/Call Ratio 0.04
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.54
MACD Signal 0.96
20-Day Bollinger Lower Band 38.89
20-Day Bollinger Middle Band 43.90
20-Day Bollinger Upper Band 48.90
Beta 1.15
RSI 46.26
50-Day SMA 48.33
150-Day SMA 32.19
200-Day SMA 30.39

System

Modified 3/28/2025 2:21:04 AM EST